Eikon Therapeutics, Inc. (EIKN) stock
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.15−0.23 (-4.36%)
Close on Nov 17, 2026Market cap $278.95MP/E –Yield –
Eikon Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Eikon Therapeutics
Eikon Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?